Please Wait.....
Report
Clinical Trials - Company Evaluation Report, 2025
Market Report I 2025-08-01 I 172 Pages I MarketsandMarkets
The Clinical Trial Supplies Companies Quadrant is a comprehensive industry analysis that provides valuable insights into the global market for Clinical Trial Supplies. This quadrant offers a detailed evaluation of key market players, technological advancements, product innovations, and emerging trends shaping the industry. MarketsandMarkets 360 Quadrants evaluated over 120 companies, of which the Top 17 Clinical Trial Supplies Companies were categorized and recognized as the quadrant leaders.
The clinical trial supplies market is experiencing significant growth, driven by the increasing complexity of clinical trials, the rise in biologics and personalized medicine, and the globalization of clinical research. To manage costs, ensure regulatory compliance, and improve logistical efficiency, pharmaceutical and biotechnology companies are increasingly outsourcing supply chain operations to specialized service providers. Key innovations such as temperature-controlled packaging, direct-to-patient (DTP) delivery models, and the rise of decentralized clinical trials are accelerating demand for advanced supply chain solutions. The growing adoption of biologics, as well as cell and gene therapies, has further increased the need for robust cold chain logistics, real-time temperature monitoring, and cryogenic storage capabilities.
Digital transformation is also reshaping clinical trial supply management. AI-powered demand forecasting, blockchain-enabled transparency, and cloud-based inventory systems are enhancing operational efficiency and data integrity. As a result, pharmaceutical and biotech firms are partnering more frequently with Contract Research Organizations (CROs) and Contract Manufacturing Organizations (CMOs) to access integrated, end-to-end clinical trial supply solutions-further fueling market expansion.
The 360 Quadrant maps the Clinical Trial Supplies companies based on criteria such as revenue, geographic presence, growth strategies, investments, and sales strategies for the market presence of the Clinical Trial Supplies quadrant. The top criteria for product footprint evaluation included Service (logistics & distribution, storage & retention, packaging, labeling and blinding, manufacturing, comparator sourcing and other services) phase (Phase III, Phase II, Phase I, Phase IV, and Phase BA/BE) type (small molecules, biologics, and medical devices) therapeutic area (oncology, neurology, respiratory disorders, metabolic disorders/endocrinology, cardiovascular system disorders, dermatology, gastrointestinal system disorders, immunological disorders, infectious diseases, psychiatry, ophthalmology, hematology, genitourinary & women's health, and other therapeutic areas).
Key Players:
Some of the prominent players are Thermo Fisher Scientific Inc. (US), Novo Holdings A/S (Denmark), Marken (UPS) (US), Eurofins Scientific (Luxembourg), Piramal Group (India), Almac Group (UK), Novo Holdings A/S (Denmark), Marken (UPS) (US), PCI Pharma Services (US), and Sharp Services LLC (US), and others. These players are increasingly focusing on product launches and enhancements, investments, partnerships, collaborations, joint ventures, funding, acquisitions, expansions, agreements, sales contracts, and alliances to strengthen their presence in the global market.
Top 3 Companies
Thermo Fisher Scientific
Thermo Fisher Scientific is a global leader in science and technology, specializing in high-end analytical instruments, laboratory equipment, consumables, reagents, software, and services that support scientific research, discovery, diagnostics, and analysis. The company operates through four primary business segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products & Biopharma Services. Thermo Fisher's presence in the clinical trial supplies market is anchored through its subsidiary PPD, which falls under the Laboratory Products & Biopharma Services segment. The company delivers a wide range of solutions through its prominent brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon, and PPD.
Sharp Services LLC
Sharp Services is a global provider of contract packaging and clinical trial supply solutions, serving the pharmaceutical, biotechnology, and life sciences industries. The company delivers end-to-end clinical trial services including GMP-compliant primary and secondary packaging, multi-language labeling, blinding services, cold chain logistics, Just-in-Time (JIT) labeling, and global storage and distribution. Sharp supports both clinical and commercial needs while ensuring regulatory compliance and operational flexibility. Headquartered in the United States, Sharp maintains GMP-certified facilities in the U.S. and the U.K., with operations extending across North America and Europe. Its key subsidiaries include Sharp Laboratories of America, Inc. (SLA), Sharp Hong Kong Limited (SHK), Sharp Manufacturing (Thailand) Co., Ltd. (SMTL), and Sharp Corporation of Australia Pty. Ltd. (SCA).
Parexel International
Parexel International is a leading contract research organization (CRO) that offers comprehensive drug development and regulatory services to pharmaceutical, biotech, and medical device companies. Its core business segment, Clinical Research Services (CRS), encompasses full-spectrum clinical trial management from Phase I to Phase IV, along with biostatistics, pharmacovigilance, data management, regulatory affairs, market access consulting, observational studies, and clinical logistics. Headquartered in the U.S., Parexel has a strong international footprint, with 85 offices across 52 countries. Notable subsidiaries include Parexel International S.A. (Argentina), Parexel Belgium SPRL, Parexel International, LLC (U.S.), Parexel International (Canada) Ltd., Parexel China Ding Hui Co., Ltd., Parexel International GmbH (Germany), Parexel International Limited (UK), and Parexel International Inc. (Japan).
1 INTRODUCTION 13
1.1 MARKET DEFINITION 13
1.2 STAKEHOLDERS 13
2 EXECUTIVE SUMMARY 14
3 MARKET OVERVIEW 19
3.1 INTRODUCTION 19
3.2 MARKET DYNAMICS 19
3.2.1 DRIVERS 20
3.2.1.1 Increasing focus on patient-centric trials (DCTs) 20
3.2.1.2 Increasing clinical trials for precision/personalized medicines supporting growth in clinical trial outsourcing 21
3.2.1.3 Rising R&D investments and patent cliff pressure driving growth in outsourcing clinical trial activities 22
3.2.1.4 Service flexibility offered by CROs for clinical development (FSP, FSO, Hybrid) 23
3.2.1.5 Technological integrations 24
3.2.2 OPPORTUNITIES 24
3.2.2.1 Increased focus on pediatric clinical trials 24
3.2.2.2 Increasing regulatory requirements for increasing diversity in clinical trials 25
3.2.2.3 Growing role of real-world evidence in drug approvals 26
3.2.2.4 Expanding drug modalities (such as CGT, Tissue Engineering, Bispecific Abs) in clinical trials 27
3.2.3 CHALLENGES 28
3.2.3.1 Cybersecurity or intellectual property concerns 28
3.2.3.2 Challenge of patient retention 29
3.2.3.3 Growing market competition 29
3.3 MARKET TRENDS 30
3.3.1 IN SILICO CLINICAL TRIALS 30
3.4 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS 30
3.5 VALUE CHAIN ANALYSIS 31
3.6 ECOSYSTEM ANALYSIS 33
3.7 TECHNOLOGY ANALYSIS 35
3.7.1 KEY TECHNOLOGIES 35
3.7.1.1 Clinical trial management system (CTMS) 35
3.7.1.2 Electronic data capture (EDC) systems 36
3.7.1.3 Randomization and trial supply management (RTSM) 36
?
3.7.2 COMPLEMENTARY TECHNOLOGIES 37
3.7.2.1 Telemedicine and wearable devices 37
3.7.2.2 AI and ML integration 37
3.8 KEY CONFERENCES AND EVENTS, 2025-2026 38
3.9 PORTER'S FIVE FORCES ANALYSIS 39
3.9.1 THREAT OF NEW ENTRANTS 40
3.9.2 THREAT OF SUBSTITUTES 41
3.9.3 BARGAINING POWER OF SUPPLIERS 41
3.9.4 BARGAINING POWER OF BUYERS 41
3.9.5 INTENSITY OF COMPETITIVE RIVALRY 41
3.10 IMPACT OF AI/GEN AI ON CLINICAL TRIAL SERVICES MARKET 42
3.10.1 INTRODUCTION 42
3.10.2 MARKET POTENTIAL FOR CLINICAL TRIALS 42
3.10.3 AI USE CASES 43
3.10.4 KEY COMPANIES IMPLEMENTING AI 44
3.10.5 FUTURE OF GENERATIVE AI IN CLINICAL TRIAL ECOSYSTEM 44
4 COMPETITIVE LANDSCAPE 45
4.1 OVERVIEW 45
4.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 45
4.3 REVENUE ANALYSIS 48
4.4 MARKET SHARE ANALYSIS, 2024 48
4.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024 51
4.5.1 STARS 51
4.5.2 EMERGING LEADERS 51
4.5.3 PERVASIVE PLAYERS 51
4.5.4 PARTICIPANTS 51
4.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024 52
4.5.5.1 Company footprint 52
4.5.5.2 Region footprint 54
4.5.5.3 Service type footprint 55
4.5.5.4 Phase footprint 56
4.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024 57
4.6.1 PROGRESSIVE COMPANIES 57
4.6.2 RESPONSIVE COMPANIES 57
4.6.3 DYNAMIC COMPANIES 57
4.6.4 STARTING BLOCKS 58
4.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024 59
4.6.5.1 Detailed list of key startups/SMEs 59
4.6.5.2 Competitive benchmarking of startups/SMEs 60
4.7 COMPANY VALUATION AND FINANCIAL METRICS 61
4.8 BRAND/SERVICE COMPARISON 62
4.9 COMPETITIVE SCENARIO 63
4.9.1 SERVICE LAUNCHES 63
4.9.2 DEALS 64
4.9.3 EXPANSIONS 65
5 COMPANY PROFILES 66
5.1 KEY PLAYERS 66
5.1.1 IQVIA INC. 66
5.1.1.1 Business overview 66
5.1.1.2 Services offered 67
5.1.1.3 Recent developments 69
5.1.1.3.1 Service launches 69
5.1.1.3.2 Deals 69
5.1.1.3.3 Expansions 71
5.1.1.4 MnM view 72
5.1.1.4.1 Right to win 72
5.1.1.4.2 Strategic choices 72
5.1.1.4.3 Weaknesses and competitive threats 72
5.1.2 ICON PLC 73
5.1.2.1 Business overview 73
5.1.2.2 Services offered 74
5.1.2.3 Recent developments 80
5.1.2.3.1 Service launches 80
5.1.2.3.2 Deals 81
5.1.2.4 MnM view 82
5.1.2.4.1 Right to win 82
5.1.2.4.2 Strategic choices 82
5.1.2.4.3 Weaknesses and competitive threats 82
5.1.3 THERMO FISHER SCIENTIFIC INC. 83
5.1.3.1 Business overview 83
5.1.3.2 Services offered 84
5.1.3.3 Recent developments 89
5.1.3.3.1 Service launches 89
5.1.3.3.2 Deals 90
5.1.3.3.3 Expansions 92
5.1.3.4 MnM view 93
5.1.3.4.1 Right to win 93
5.1.3.4.2 Strategic choices 93
5.1.3.4.3 Weaknesses and competitive threats 93
5.1.4 FORTREA 94
5.1.4.1 Business overview 94
5.1.4.2 Services offered 95
5.1.4.3 Recent developments 99
5.1.4.3.1 Service launches 99
5.1.4.3.2 Deals 99
5.1.4.3.3 Expansions 100
5.1.4.4 MnM view 100
5.1.4.4.1 Right to win 100
5.1.4.4.2 Strategic choices 100
5.1.4.4.3 Weaknesses and competitive threats 100
5.1.5 SYNEOS HEALTH 101
5.1.5.1 Business overview 101
5.1.5.2 Services offered 102
5.1.5.3 Recent developments 103
5.1.5.3.1 Service launches 103
5.1.5.3.2 Deals 103
5.1.5.4 MnM view 106
5.1.5.4.1 Right to win 106
5.1.5.4.2 Strategic choices 106
5.1.5.4.3 Weaknesses and competitive threats 106
5.1.6 LABORATORY CORPORATION OF AMERICA HOLDINGS 107
5.1.6.1 Business overview 107
5.1.6.2 Services offered 109
5.1.6.3 Recent developments 109
5.1.6.3.1 Service launches 109
5.1.6.3.2 Deals 110
5.1.6.3.3 Expansions 111
5.1.6.4 MnM view 112
5.1.6.4.1 Right to win 112
5.1.6.4.2 Strategic choices 112
5.1.6.4.3 Weaknesses and competitive threats 112
5.1.7 MEDPACE 113
5.1.7.1 Business overview 113
5.1.7.2 Services offered 114
5.1.8 WUXI APPTEC 117
5.1.8.1 Business overview 117
5.1.8.2 Services offered 118
5.1.8.3 Recent developments 121
5.1.8.3.1 Deals 121
5.1.9 FRONTAGE LABS 122
5.1.9.1 Business overview 122
5.1.9.2 Services offered 123
5.1.9.3 Recent developments 124
5.1.9.3.1 Deals 124
5.1.9.3.2 Expansions 125
5.1.10 PHARMARON 126
5.1.10.1 Business overview 126
5.1.10.2 Services offered 128
5.1.11 TIGERMED 129
5.1.11.1 Business overview 129
5.1.11.2 Services offered 130
5.1.11.3 Recent developments 132
5.1.11.3.1 Service approvals 132
5.1.11.3.2 Deals 133
5.1.12 SGS SOCIETE GENERALE DE SURVEILLANCE SA 134
5.1.12.1 Business overview 134
5.1.12.2 Services offered 135
5.1.13 EUROFINS SCIENTIFIC 136
5.1.13.1 Business overview 136
5.1.13.2 Services offered 138
5.1.14 LINICAL 139
5.1.14.1 Business overview 139
5.1.14.2 Services offered 141
5.1.14.3 Recent developments 141
5.1.14.3.1 Deals 141
5.1.14.3.2 Expansions 142
5.1.15 PAREXEL INTERNATIONAL CORPORATION 143
5.1.15.1 Business overview 143
5.1.15.2 Services offered 144
5.1.15.3 Recent developments 145
5.1.15.3.1 Service launches 145
5.1.15.3.2 Deals 145
5.1.15.3.3 Expansions 147
5.2 OTHER PLAYERS 148
5.2.1 WORLDWIDE CLINICAL TRIALS 148
5.2.2 PROPHARMA 150
5.2.3 NOVOTECH 151
5.2.4 PSI 154
5.2.5 ALLUCENT 155
5.2.6 PREMIER RESEARCH 156
5.2.7 CAIDYA 157
5.2.8 ERGOMED GROUP 158
5.2.9 CLARIO 160
5.2.10 PRECISION MEDICINE GROUP, LLC. 161
5.2.11 ADVANCED CLINICAL 162
5.2.12 EPS HOLDINGS, INC. 163
5.2.13 GUIRES INC. (PEPGRA) 164
5.2.14 KCR S.A. 165
6 APPENDIX 166
6.1 RESEARCH METHODOLOGY 166
6.1.1 RESEARCH DATA 166
6.1.1.1 Secondary data 166
6.1.1.2 Primary data 167
6.1.2 RESEARCH ASSUMPTIONS 167
6.1.3 RESEARCH LIMITATIONS 168
6.2 COMPANY EVALUATION MATRIX: METHODOLOGY 169
6.3 AUTHOR DETAILS 172
TABLE 1 CLINICAL TRIAL SERVICES MARKET: IMPACT ANALYSIS OF MARKET DYNAMICS 20
TABLE 2 CLINICAL TRIAL SERVICES MARKET: ROLE OF COMPANIES IN ECOSYSTEM 34
TABLE 3 CLINICAL TRIAL SERVICES MARKET: KEY CONFERENCES AND EVENTS,
2025-2026 38
TABLE 4 CLINICAL TRIAL SERVICES MARKET: PORTER'S FIVE FORCES ANALYSIS 39
TABLE 5 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN CLINICAL
TRIAL SERVICES MARKET, JANUARY 2021-JANUARY 2025 45
TABLE 6 CLINICAL TRIAL SERVICES MARKET: DEGREE OF COMPETITION, 2024 49
TABLE 7 CLINICAL TRIAL SERVICES MARKET: REGION FOOTPRINT 54
TABLE 8 CLINICAL TRIAL SERVICES MARKET: SERVICE TYPE FOOTPRINT 55
TABLE 9 CLINICAL TRIAL SERVICES MARKET: PHASE FOOTPRINT 56
TABLE 10 CLINICAL TRIAL SERVICES MARKET: DETAILED LIST OF KEY STARTUP/SMES 59
TABLE 11 CLINICAL TRIAL SERVICES MARKET: COMPETITIVE BENCHMARKING OF
KEY STARTUPS/SMES 60
TABLE 12 CLINICAL TRIAL SERVICES MARKET: SERVICE LAUNCHES,
JANUARY 2021-JANUARY 2025 63
TABLE 13 CLINICAL TRIAL SERVICES MARKET: DEALS, JANUARY 2021-JANUARY 2025 64
TABLE 14 CLINICAL TRIAL SERVICES MARKET: EXPANSIONS, JANUARY 2021-JANUARY 2025 65
TABLE 15 IQVIA INC.: COMPANY OVERVIEW 66
TABLE 16 IQVIA INC.: SERVICES OFFERED 67
TABLE 17 IQVIA INC.: SERVICE LAUNCHES, JANUARY 2021-JANUARY 2025 69
TABLE 18 IQVIA INC.: DEALS, JANUARY 2021-JANUARY 2025 69
TABLE 19 IQVIA INC.: EXPANSIONS, JANUARY 2021-JANUARY 2025 71
TABLE 20 ICON PLC: COMPANY OVERVIEW 73
TABLE 21 ICON PLC: SERVICES OFFERED 74
TABLE 22 ICON PLC: SERVICE LAUNCHES, JANUARY 2021-JANUARY 2025 80
TABLE 23 ICON PLC: DEALS, JANUARY 2021-JANUARY 2025 81
TABLE 24 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW 83
TABLE 25 THERMO FISHER SCIENTIFIC INC.: SERVICES OFFERED 84
TABLE 26 THERMO FISHER SCIENTIFIC INC.: SERVICE LAUNCHES,
JANUARY 2021-JANUARY 2025 89
TABLE 27 THERMO FISHER SCIENTIFIC INC.: DEALS, JANUARY 2021-JANUARY 2025 90
TABLE 28 THERMO FISHER SCIENTIFIC INC.: EXPANSIONS, JANUARY 2021-JANUARY 2025 92
TABLE 29 FORTREA: COMPANY OVERVIEW 94
TABLE 30 FORTREA: SERVICES OFFERED 95
TABLE 31 FORTREA: SERVICE LAUNCHES, JANUARY 2021-JANUARY 2025 99
TABLE 32 FORTREA: DEALS, JANUARY 2021-JANUARY 2025 99
TABLE 33 FORTREA: EXPANSIONS, JANUARY 2021-JANUARY 2025 100
TABLE 34 SYNEOS HEALTH: COMPANY OVERVIEW 101
TABLE 35 SYNEOS HEALTH: SERVICES OFFERED 102
TABLE 36 SYNEOS HEALTH: SERVICE LAUNCHES, JANUARY 2021-JANUARY 2025 103
TABLE 37 SYNEOS HEALTH: DEALS, JANUARY 2021-JANUARY 2025 103
TABLE 38 LABORATORY CORPORATION OF AMERICA HOLDINGS: COMPANY OVERVIEW 107
TABLE 39 LABORATORY CORPORATION OF AMERICA HOLDINGS: SERVICES OFFERED 109
TABLE 40 LABORATORY CORPORATION OF AMERICA HOLDINGS: SERVICE LAUNCHES, JANUARY 2021-JANUARY 2025 109
TABLE 41 LABORATORY CORPORATION OF AMERICA HOLDINGS:
DEALS, JANUARY 2021-JANUARY 2025 110
TABLE 42 LABORATORY CORPORATION OF AMERICA HOLDINGS:
EXPANSIONS, JANUARY 2021-JANUARY 2025 111
TABLE 43 MEDPACE: COMPANY OVERVIEW 113
TABLE 44 MEDPACE: SERVICES OFFERED 114
TABLE 45 WUXI APPTEC: COMPANY OVERVIEW 117
TABLE 46 WUXI APPTEC: SERVICES OFFERED 118
TABLE 47 WUXI APPTEC: DEALS, JANUARY 2021-JANUARY 2025 121
TABLE 48 FRONTAGE LABS: COMPANY OVERVIEW 122
TABLE 49 FRONTAGE LABS: SERVICES OFFERED 123
TABLE 50 FRONTAGE LABS: DEALS, JANUARY 2021-JANUARY 2025 124
TABLE 51 FRONTAGE LABS: EXPANSIONS, JANUARY 2021-JANUARY 2025 125
TABLE 52 PHARMARON: COMPANY OVERVIEW 126
TABLE 53 PHARMARON: SERVICES OFFERED 128
TABLE 54 TIGERMED: COMPANY OVERVIEW 129
TABLE 55 TIGERMED: SERVICES OFFERED 130
TABLE 56 TIGERMED: SERVICE APPROVALS, JANUARY 2021-JANUARY 2025 132
TABLE 57 TIGERMED: DEALS, JANUARY 2021-JANUARY 2025 133
TABLE 58 SGS SOCIETE GENERALE DE SURVEILLANCE SA: COMPANY OVERVIEW 134
TABLE 59 SGS SOCIETE GENERALE DE SURVEILLANCE SA.: SERVICES OFFERED 135
TABLE 60 EUROFINS SCIENTIFIC: COMPANY OVERVIEW 136
TABLE 61 EUROFINS SCIENTIFIC: SERVICES OFFERED 138
TABLE 62 LINICAL: COMPANY OVERVIEW 139
TABLE 63 LINICAL: SERVICES OFFERED 141
TABLE 64 LINICAL: DEALS, JANUARY 2021-JANUARY 2025 141
TABLE 65 LINICAL: EXPANSIONS, JANUARY 2021-JANUARY 2025 142
TABLE 66 PAREXEL INTERNATIONAL CORPORATION: COMPANY OVERVIEW 143
TABLE 67 PAREXEL INTERNATIONAL CORPORATION: SERVICES OFFERED 144
TABLE 68 PAREXEL INTERNATIONAL CORPORATION: SERVICE LAUNCHES,
JANUARY 2021-JANUARY 2025 145
TABLE 69 PAREXEL INTERNATIONAL CORPORATION: DEALS, JANUARY 2021-JANUARY 2025 145
TABLE 70 PAREXEL INTERNATIONAL CORPORATION: EXPANSIONS,
JANUARY 2021-JANUARY 2025 147
TABLE 71 WORLDWIDE CLINICAL TRIALS: COMPANY OVERVIEW 148
TABLE 72 PROPHARMA: COMPANY OVERVIEW 150
TABLE 73 NOVOTECH: COMPANY OVERVIEW 151
TABLE 74 PSI: COMPANY OVERVIEW 154
TABLE 75 ALLUCENT: COMPANY OVERVIEW 155
TABLE 76 PREMIER RESEARCH: COMPANY OVERVIEW 156
TABLE 77 CAIDYA: COMPANY OVERVIEW 157
TABLE 78 ERGOMED GROUP: COMPANY OVERVIEW 158
TABLE 79 CLARIO: COMPANY OVERVIEW 160
TABLE 80 PRECISION MEDICINE GROUP, LLC: COMPANY OVERVIEW 161
TABLE 81 ADVANCED CLINICAL: COMPANY OVERVIEW 162
TABLE 82 EPS HOLDINGS, INC.: COMPANY OVERVIEW 163
TABLE 83 GUIRES INC. (PEPGRA): COMPANY OVERVIEW 164
TABLE 84 KCR S.A.: COMPANY OVERVIEW 165
TABLE 85 RISK ASSESSMENT 169
FIGURE 1 CLINICAL TRIAL SERVICES MARKET, BY SERVICE TYPE,
2025 VS. 2030 (USD MILLION) 14
FIGURE 2 CLINICAL TRIAL SERVICES MARKET, BY THERAPEUTIC AREA,
2025 VS. 2030 (USD MILLION) 15
FIGURE 3 CLINICAL TRIAL SERVICES MARKET, BY DELIVERY MODEL, 2024 (USD MILLION) 16
FIGURE 4 CLINICAL TRIAL SERVICES MARKET, BY MODALITY, 2024 (USD MILLION) 16
FIGURE 5 CLINICAL TRIAL SERVICES MARKET, BY END USER, 2025 VS. 2030 (USD MILLION) 17
FIGURE 6 ASIA PACIFIC TO REGISTER HIGHEST CAGR IN CLINICAL
TRIAL SERVICES MARKET DURING FORECAST PERIOD 18
FIGURE 7 DRIVERS, OPPORTUNITIES, AND CHALLENGES IN CLINICAL
TRIAL SERVICES MARKET 19
FIGURE 8 R&D SPEND OF LARGE PHARMACEUTICAL COMPANIES,
2014-2023 (USD BILLION) 22
FIGURE 9 BIOSIMILAR APPROVALS IN US, 2015-2024 23
FIGURE 10 NUMBER OF CLINICAL TRIALS FOR VARIOUS MODALITIES 27
FIGURE 11 TRENDS/DISRUPTIONS INFLUENCING CUSTOMER BUSINESS 31
FIGURE 12 CLINICAL TRIAL SERVICES MARKET: VALUE CHAIN ANALYSIS 32
FIGURE 14 CLINICAL TRIAL SERVICES MARKET: PORTER'S FIVE FORCES ANALYSIS 40
FIGURE 15 CLINICAL TRIAL SERVICES MARKET: REVENUE ANALYSIS OF KEY PLAYERS,
2022-2024 (USD MILLION) 48
FIGURE 16 CLINICAL TRIAL SERVICES MARKET SHARE ANALYSIS, 2024 49
FIGURE 17 CLINICAL TRIAL SERVICES MARKET: COMPANY EVALUATION MATRIX
(KEY PLAYERS), 2024 52
FIGURE 18 CLINICAL TRIAL SERVICES MARKET: COMPANY FOOTPRINT 53
FIGURE 19 CLINICAL TRIAL SERVICES MARKET:
COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024 58
FIGURE 20 CLINICAL TRIAL SERVICES MARKET: YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS, 2024 61
FIGURE 21 CLINICAL TRIAL SERVICES MARKET: EV/EBITDA OF KEY VENDORS, 2024 61
FIGURE 22 CLINICAL TRIAL SERVICES MARKET: BRAND/SERVICE COMPARISON 62
FIGURE 23 IQVIA INC.: COMPANY SNAPSHOT (2024) 67
FIGURE 24 ICON PLC: COMPANY SNAPSHOT (2023) 74
FIGURE 25 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2023) 84
FIGURE 26 FORTREA: COMPANY SNAPSHOT (2023) 95
FIGURE 27 LABORATORY CORPORATION OF AMERICA HOLDINGS:
COMPANY SNAPSHOT (2023) 108
FIGURE 28 MEDPACE: COMPANY SNAPSHOT (2024) 114
FIGURE 29 WUXI APPTEC: COMPANY SNAPSHOT (2023) 118
FIGURE 30 FRONTAGE LABS: COMPANY SNAPSHOT (2023) 123
FIGURE 31 PHARMARON: COMPANY SNAPSHOT (2023) 127
FIGURE 32 TIGERMED: COMPANY SNAPSHOT (2023) 130
FIGURE 33 SGS SOCIETE GENERALE DE SURVEILLANCE SA: COMPANY SNAPSHOT (2023) 135
FIGURE 34 EUROFINS SCIENTIFIC: COMPANY SNAPSHOT (2024) 137
FIGURE 35 LINICAL: COMPANY SNAPSHOT (2023) 140
FIGURE 36 RESEARCH DESIGN 166
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security